Going Upstream in Time and Path May Bring APP Success
By Anette Breindl
Monday, July 23, 2012
Anyone who thinks that the term "the dismal science" refers to economics is clearly not involved in clinical trials for Alzheimer's disease, an indication which has dashed the last 13 Phase III trials attempting to make a dent in it.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.